Lee Danner & Bass Inc. grew its position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 32.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,185 shares of the company's stock after acquiring an additional 8,870 shares during the quarter. Lee Danner & Bass Inc.'s holdings in Henry Schein were worth $2,478,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Investment Management Corp VA ADV bought a new stake in Henry Schein in the fourth quarter valued at about $32,000. Rakuten Securities Inc. acquired a new stake in Henry Schein during the first quarter valued at approximately $34,000. Smartleaf Asset Management LLC grew its stake in shares of Henry Schein by 23.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock valued at $52,000 after purchasing an additional 143 shares during the period. UMB Bank n.a. raised its holdings in shares of Henry Schein by 23.2% in the 1st quarter. UMB Bank n.a. now owns 1,066 shares of the company's stock worth $73,000 after buying an additional 201 shares in the last quarter. Finally, Menard Financial Group LLC acquired a new position in shares of Henry Schein in the 4th quarter worth approximately $92,000. Institutional investors own 96.62% of the company's stock.
Henry Schein Price Performance
NASDAQ:HSIC traded up $0.19 during mid-day trading on Friday, reaching $74.67. 699,008 shares of the company were exchanged, compared to its average volume of 1,722,429. The company has a quick ratio of 0.75, a current ratio of 1.38 and a debt-to-equity ratio of 0.50. The stock has a market cap of $9.09 billion, a PE ratio of 23.33, a PEG ratio of 2.41 and a beta of 0.87. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $82.49. The company has a fifty day moving average of $70.70 and a 200 day moving average of $71.19.
Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.11 by $0.04. The business had revenue of $3.17 billion for the quarter, compared to analysts' expectations of $3.24 billion. Henry Schein had a net margin of 3.21% and a return on equity of 14.87%. Henry Schein's revenue was down .1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.10 earnings per share. On average, research analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on HSIC. Barrington Research lowered their price target on Henry Schein from $90.00 to $86.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Wall Street Zen downgraded shares of Henry Schein from a "buy" rating to a "hold" rating in a research note on Thursday, April 17th. Piper Sandler dropped their target price on shares of Henry Schein from $83.00 to $77.00 and set an "overweight" rating for the company in a research report on Wednesday, April 30th. Finally, Wells Fargo & Company cut their price target on shares of Henry Schein from $80.00 to $75.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Six equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Henry Schein has an average rating of "Moderate Buy" and an average price target of $79.30.
View Our Latest Stock Analysis on Henry Schein
About Henry Schein
(
Free Report)
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Read More

Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.